# Perioperative Outcomes of Total Vaginal Hysterectomy Versus Total Abdominal Hysterectomy: A Study of the Enlarged Uterus with Uterine Prolapse from Romania

**Authors:** Mihnea Nicodin, Laura Nicodin-Tigoianu, Anca Popescu, Mariam Dalaty, Diana Badiu, Lucian Cristian Petcu, Ovidiu Nicodin, Cristian Delcea, Nicolae Suciu

PMC · DOI: 10.3390/medicina62020321 · 2026-02-04

## TL;DR

This study compares vaginal and abdominal hysterectomy outcomes for enlarged uteri with prolapse, finding vaginal surgery offers faster recovery and fewer complications.

## Contribution

Demonstrates the feasibility and benefits of TVH for enlarged uteri with prolapse, challenging its less frequent use compared to TAH.

## Key findings

- TVH resulted in shorter operative time, less blood loss, and shorter hospital stays compared to TAH.
- Post-operative complications and adhesions were more common in the TAH group.
- Uterine size reduction techniques were successfully used in most TVH cases.

## Abstract

Background and Objectives: Total vaginal hysterectomy (TVH) has been performed quite often for a uterus with prolapse, although less used than total abdominal hysterectomy (TAH). The purpose of this study was to compare the perioperative outcomes of patients who underwent either TVH or TAH for a uterus with a weight between 250 and 300 g and uterine prolapse (UP). Materials and Methods: In this retrospective study, 180 hysterectomies were planned for women with UP between 2020 and 2024 in a tertiary center in Romania. Patients were diagnosed based on clinical symptomatology and transabdominal ultrasound. All hysterectomies were performed by the same surgeon and were divided into two groups: TVH group (n = 90) and TAH group (n = 90). Patients’ characteristics like age, uterine weight, body mass index (BMI), parity, operative time, intra-operative blood loss, hospital stay, medical history, surgical history, intra- and post-operative complications, and adhesions were evaluated. Results: No significant differences were found between groups in terms of mean age, uterine weight, BMI, or parity. TVH was associated with significantly shorter operative time, lower intra-operative blood loss, and reduced hospital stay compared to TAH (p < 0.001). Both medical and surgical histories were more common in the TAH group compared with the TVH group. However, post-operative complications were slightly more frequent in the TAH group (9.99% vs. 3.33%), as were adhesions (33.33% vs. 13.33%). Uterine hemisection, tactical myomectomy, or morcellation were used in most cases to obtain a reduction in uterine size for the TVH group (81.11%). Conclusions: Our results showed that shorter operating time, lower intra-operative blood loss, and reduced hospital stay support the use of TVH in the case of an enlarged uterus with UP. The present study showed that all patients requiring hysterectomy for such conditions can be offered TVH, which could represent a better therapy option.

## Full-text entities

- **Genes:** GNRH1 (gonadotropin releasing hormone 1) [NCBI Gene 2796] {aka GNRH, GRH, LHRH, LNRH}
- **Diseases:** asthma (MESH:D001249), cholecystectomy (MESH:D017562), chronic kidney disease (MESH:D051436), cervical dysplasia (MESH:D002578), anxiety syndrome (MESH:D001007), blood loss (MESH:D016063), adnexal disease (MESH:D000291), ureteral injuries (MESH:D014515), congenital weakness (MESH:D018908), malignancies (MESH:D009369), endometriosis (MESH:D004715), pain (MESH:D010146), retroperitoneal bleeding (MESH:D012186), dyslipidemia (MESH:D050171), mastectomy (MESH:D000072656), seroma (MESH:D049291), benign disease (MESH:D004194), injury to (MESH:D014947), complication (MESH:D008107), bladder injury (MESH:D001745), rectocele (MESH:D020047), stroke (MESH:D020521), pelvic inflammatory disease (MESH:D000292), bleeding (MESH:D006470), adenomyosis (MESH:D062788), osteoporosis (MESH:D010024), wound infection (MESH:D014946), UTI (MESH:D014552), menorrhagia (MESH:D008595), gastrointestinal (MESH:D005767), infection (MESH:D007239), cystocele (MESH:D052858), dysmenorrhea (MESH:D004412), CENTRAL (MESH:D020210), pelvic pain (MESH:D017699), back pain (MESH:D001416), blood (MESH:D006402), hypertension (MESH:D006973), hypothyroidism (MESH:D007037), adhesions (MESH:D000267), rheumatoid arthritis (MESH:D001172), abnormal uterine bleeding (MESH:D014592), anemia (MESH:D000740), UP (MESH:D014596), prolapse (MESH:D011391), postpartum hemorrhage (MESH:D006473), ileus (MESH:D045823), TVH (MESH:D014627), constipation (MESH:D003248), heart disease (MESH:D006331), endometrial hyperplasia (MESH:D004714), depressive syndrome (MESH:D003866), type 2 diabetes (MESH:D003924), fibroids (MESH:D007889)
- **Chemicals:** meperidine (MESH:D008614), acetaminophen (MESH:D000082), saline (MESH:D012965), cephalosporin (MESH:D002511), TAH (-), povidone-iodine (MESH:D011206)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941907/full.md

---
Source: https://tomesphere.com/paper/PMC12941907